WVE
Wave Life Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Low Beta
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About WVE
Wave Life Sciences Ltd.
A biotechnology company that develops and commercializes nucleic acid therapies for genetic diseases
Pharmaceutical
07/23/2012
11/11/2015
NASDAQ Stock Exchange
287
12-31
Common stock
7 Straits View #12-00, Marina One East Tower, Singapore 018936
--
Wave Life Sciences Ltd., was incorporated in Singapore on July 23, 2012.
The company is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA drugs (also known as oligonucleotides) or targeted ribonucleic acids (" RNA ") to transform human health. The company's RNA drug platform, PRISMTM, combines multiple models, chemical innovations and insights into human genetics to provide scientific breakthroughs in the treatment of rare and endemic diseases. The Company's RNA Targeting Pattern Toolkit, which includes RNA editing, splicing, antisense silencing and RNA interference (" RNAi "), provides the Company with a unique capability to design and sustainably deliver drug candidates that best address disease biology. The Company leads projects involving rare and prevalent diseases including α-1 antitrypsin deficiency (" AATD "), obesity, Duchenne muscular dystrophy (" DMD ") and Huntington's disease (" HD ").
Earnings Call
Q2/2025
Estimate EPS-0.28
Actual EPS-0.31
Estimate Revenue9.64M
Actual Revenue8.70M
Wave Life Sciences' Q2 2025: Unraveling Key Contradictions in INHBE Program and Activin E Strategy
Jul 31,2025 02:56
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
WVE has released its 2025 Q3 earnings. EPS was reported at -0.32, versus the expected -0.3, missing expectations. The chart below visualizes how WVE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
WVE has released its 2025 Q3 earnings report, with revenue of 7.61M, reflecting a YoY change of 199.11%, and net profit of -53.85M, showing a YoY change of 12.83%. The Sankey diagram below clearly presents WVE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
